Skip to main content
Elsevier
View Cart

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3

Translational and Clinical Outcomes

  • 1st Edition - April 15, 2022
  • Latest edition
  • Editors: Ganji Purnachandra Nagaraju, Sarfraz Ahmad
  • Language: English

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma: Translational and Clinical Outcomes, Volume Three provides comprehensive information about ong… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma: Translational and Clinical Outcomes, Volume Three provides comprehensive information about ongoing research and clinical data on liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. This updated volume discusses topics such as clinical and safety assessment of HCC patients, liver transplantation as a therapeutic option, immunotherapy interventions, and image-based surveillance. In addition, it discusses immunohistology of HCC-enabled precision medicine and artificial intelligence for hepatocellular carcinomas.

This is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.

Key features

  • Provides best practices for the management of hepatocellular carcinoma in the clinical setting
  • Discusses emerging treatment approaches based on artificial intelligence and precision medicine tools and techniques
  • Brings updated information on international clinical trials for the treatment of HCC

Readership

Cancer researchers, oncologists. Medical doctors, hepathologists, graduate students

Table of contents

1. Clinical and safety assessment of the HCC patients2. Liver transplantation for HCC therapy3. Clinical trials for HCC in the diagnosis and therapy: An international perspective4. Recent advancements in immunotherapy interventions for the management of HCC5. Role of genetic insights and tumor microenvironment in HCC: New opportunities for gene therapy6. An Update on the treatment of hepatocellular carcinoma7. An update of image-based surveillance in HCC8. Meta-analysis of PD-1/PD-L1 inhibitors in advanced HCC9. Towards a personalized medicine approach for the treatment of HCC10. Precision medicine in the theranostics of HCC11. Immunohistology of HCC-enabled precision medicine12. Artificial Intelligence and Precision Medicine for HCC13. Genomics-Enabled Precision Medicine for HCC

Product details

  • Edition: 1
  • Latest edition
  • Published: April 21, 2022
  • Language: English

About the editors

GN

Ganji Purnachandra Nagaraju

Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books for Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).
Affiliations and expertise
Assistant Professor, School of Medicine, Division of Hematology and Oncology, University of Alabama, Birmingham, AL, USA

SA

Sarfraz Ahmad

Prof. Sarfraz Ahmad is Director of Clinical Research at Gynecologic Oncology Program of AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad’s research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 275 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments
Affiliations and expertise
AdventHealth Cancer Institute, Orlando, FL, United States

View book on ScienceDirect

Read Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 on ScienceDirect